> Exoxemis as a Partner Applying highest quality science, research, and development to our partnerships and collaborations. more >> > Licensing We leverage our proprietary know-how and technology platform through product licensing and collaborations in areas of unmet clinical need. > E-mail Inqui...

> Nosocomial Infections Multiple MPO formulations are in development for prevention of serious, and often resistant, hospital-acquired infections. more >> > Surgical Site Infection Prevention Our unique MPO formulation holds the promise of a breakthrough in surgical site infection prevention. > B...

> Posters > News Exoxemis scientific team members are active contributors to the fields body of knowledge in MPO technology. > Haloperoxidase Literature An extensive literature on haloperoxidases supports the broad microbicidal activity of MPO and EPO. more >> > E-mail Inquiries News February 23,...

Site Map Home Technology Haloperoxidase Enzymes MPO and EPO provide the basis for safe, broad-spectrum microbicidal agents against serious and resistant infections. Efficacy and Safety Pre-clinical studies indicate that MPO and EPO are non-toxic, non-irritating, non-genotoxic, and non-sensitizing in...

> Nosocomial Infections Multiple MPO formulations are in development for prevention of serious, and often resistant, hospital-acquired infections. more >> > Surgical Site Infection Prevention Our unique MPO formulation holds the promise of a breakthrough in surgical site infection prevention. mor...